drugset
drugset / Trial / NCT00209963

A Study of Gaboxadol in Primary Insomnia

NCT00209963 ↗

Phase 3 Completed 600 enrolled H. Lundbeck A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the safety and tolerability of gaboxadol in primary insomnia.

Timeline

Start
2003-06
Primary completion
—
Completion
2005-03

Drugs

EvaluationDrugModalityDoseRoute
Subject gaboxadol Small molecule — —

Indications

insomnia